K
Keith W. Orford
Researcher at Harvard University
Publications - 8
Citations - 1096
Keith W. Orford is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 992 citations.
Papers
More filters
Journal ArticleDOI
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation
Keith W. Orford,David T. Scadden +1 more
TL;DR: The relationship that exists between cell-cycle progression and the self-renewal versus commitment cell-fate decision in embryonic and adult stem cells is deconstructed.
Journal ArticleDOI
Differential H3K4 methylation identifies developmentally poised hematopoietic genes.
Keith W. Orford,Peter V. Kharchenko,Peter V. Kharchenko,Weil R. Lai,Maria Carlota Dao,David J. Worhunsky,Adam Ferro,Viktor Janzen,Peter J. Park,Peter J. Park,David T. Scadden +10 more
TL;DR: Assessment of histone H3 lysine 4 dimethylation and trimethylation on a genome-wide scale in erythroid development reveals distinct epigenetic regulation of CGI and non-CGI genes during development and indicates an interactive relationship between DNA sequence and differential H3K4 methylation in lineage-specific differentiation.
Journal ArticleDOI
Genome-wide Map of Nuclear Protein Degradation Shows NCoR1 Turnover as a Key to Mitochondrial Gene Regulation
Andre Catic,Carol Y. Suh,Cedric T. Hill,Laurence Daheron,Theresa Henkel,Theresa Henkel,Keith W. Orford,David Dombkowski,Tao Liu,X. Shirley Liu,David T. Scadden +10 more
TL;DR: The genome-wide map described here ties proteolysis in mammalian cells to active enhancers and to promoters of specific gene families and identifies proteolytic derepression as highly dynamic in regulating the transcription of genes involved in energy metabolism.
Journal ArticleDOI
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Nizar M. Tannir,Neeraj Agarwal,Camillo Porta,Nicola Jane Lawrence,Robert J. Motzer,Bradley Alexander McGregor,Richard T. Lee,Rohit Jain,Nancy B. Davis,Leonard Joseph Appleman,Oscar B. Goodman,Walter M. Stadler,Sunil G. Gandhi,Daniel M. Geynisman,Roberto Iacovelli,Begoña Mellado,J. M. S. Sepulveda Sanchez,Robert A. Figlin,Thomas Powles,Lalith Akella,Keith W. Orford,Bernard Escudier +21 more
TL;DR: In this randomized clinical trial, telaglenastat did not improve the efficacy of cabozantinib in metastatic RCC and Tela + Cabo was well tolerated with AEs consistent with the known risks of both agents.
Journal ArticleDOI
Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.
Chung-Han Lee,Robert J. Motzer,Hamid Emamekhoo,Marc R. Matrana,I. Percent,James J. Hsieh,Arif Hussain,Ulka N. Vaishampayan,Sandy T. Liu,Steven McCune,Vijay Patel,Montaser Shaheen,Johanna C. Bendell,Alice C. Fan,Benjamin A. Gartrell,Oscar B. Goodman,Petros Nikolinakos,Arash Rezazadeh Kalebasty,Yousef Zakharia,Zhentao Zhang,Hema Parmar,Lalith Akella,Keith W. Orford,Nizar M. Tannir +23 more
TL;DR: In this article , a phase 1 trial of 2L+ renal cell carcinoma (RCC) patients was conducted, where the authors evaluated the combination of telaglenastat plus everolimus (TelaE) versus PboE (PboE) in patients with advanced/metastatic RCC in the 3L+ setting.